<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Joint aspiration or injection in adults: Complications</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Joint aspiration or injection in adults: Complications</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Joint aspiration or injection in adults: Complications</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">W Neal Roberts, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Howard W Hauptman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel E Furst, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A needle is inserted into a joint for two main indications: aspiration of fluid (arthrocentesis) for diagnosis or for injection of medications. In practical terms, most injections into joints consist of a glucocorticoid, a local anesthetic, or combinations of the two. Soft tissue and intraarticular glucocorticoid injections are generally safe, but they can result in systemic and local adverse effects.</p><p>The complications of joint aspiration or glucocorticoid injection in adults are discussed here. Complications of these procedures in children, more details on septic arthritis and bursitis, and other aspects of joint and soft tissue aspiration and injection are described elsewhere, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Complications of joint aspiration and injection in children (see  <a class="medical medical_review" href="/d/html/6425.html" rel="external">"Joint aspiration or injection in children: Indications, technique, and complications"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Septic arthritis and bursitis (see  <a class="medical medical_review" href="/d/html/7666.html" rel="external">"Septic arthritis in adults"</a> and  <a class="medical medical_review" href="/d/html/7650.html" rel="external">"Septic bursitis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Joint aspiration and injection indications and technique in adults and children (see  <a class="medical medical_review" href="/d/html/7986.html" rel="external">"Joint aspiration or injection in adults: Technique and indications"</a> and  <a class="medical medical_review" href="/d/html/6425.html" rel="external">"Joint aspiration or injection in children: Indications, technique, and complications"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medication dosing in and frequency of joint and soft tissue injections (see  <a class="medical medical_review" href="/d/html/7985.html" rel="external">"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Synovial fluid analysis (see  <a class="medical medical_review" href="/d/html/1828.html" rel="external">"Synovial fluid analysis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adverse effects of glucocorticoids (see  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Role of injections in treatment of osteoarthritis and rheumatoid arthritis (see  <a class="medical medical_review" href="/d/html/112192.html" rel="external">"Management of moderate to severe knee osteoarthritis", section on 'Limited role of intraarticular glucocorticoid injections'</a> and  <a class="medical medical_review" href="/d/html/7491.html" rel="external">"Initial treatment of rheumatoid arthritis in adults", section on 'Intraarticular glucocorticoids'</a>)</p><p></p><p class="headingAnchor" id="H1294098427"><span class="h1">INFECTIOUS COMPLICATIONS</span></p><p class="headingAnchor" id="H3337324293"><span class="h2">Septic arthritis</span><span class="headingEndMark"> — </span>Iatrogenic septic arthritis from a joint procedure is a rare but serious complication that occurs in 1 of every 1000 to 3000 procedures [<a href="#rid1">1,2</a>]. A nationwide study in Iceland using data from all arthrocentesis procedures performed over a 13-year period reported frequency of septic arthritis of 1 of 2600 procedures [<a href="#rid1">1</a>]. Another large registry study of 22,370 procedures found a similar rate of septic arthritis of 1 of 2030 procedures [<a href="#rid2">2</a>].</p><p>The rates of iatrogenic infections can be reduced by using appropriate measures when performing joint aspirations or injections [<a href="#rid3">3</a>]. These measures include the following: (See  <a class="medical medical_review" href="/d/html/7986.html" rel="external">"Joint aspiration or injection in adults: Technique and indications", section on 'Sterile preparation'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Using triple concentric iodine preparation of the skin or <a class="drug drug_general" data-topicid="9244" href="/d/drug information/9244.html" rel="external">chlorhexidine</a> preparation, rather than just alcohol alone</p><p class="bulletIndent1"><span class="glyph">●</span>"No touch" technique if using nonsterile universal precaution gloves</p><p class="bulletIndent1"><span class="glyph">●</span>Single-dose vials when these are available from the institutional supplies (multidose vials are most common in outpatient and office practices)</p><p class="bulletIndent1"><span class="glyph">●</span>Changing to a new needle after drawing up the medication and before injecting it</p><p class="bulletIndent1"><span class="glyph">●</span>Cleaning the tops of the vials with an alcohol swipe prior to drawing up the injection</p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding preparing the syringe many hours, or days, ahead of when it is to be used</p><p></p><p>Although all needle sizes can theoretically inoculate a joint by depositing a core of tissue within the joint [<a href="#rid4">4</a>], there is some evidence from animal models suggesting that translocation of bacteria is correlated both with needle size and with overlying infected tissue (aspirating through cellulitis) [<a href="#rid5">5</a>]. However, there are no human data to support using a preferred needle size to reduce the risk of translocation of bacteria during joint aspiration. Presumably, aspirating through cellulitis would be less of a concern if the patient has already been established on an antibiotic regimen. In addition, ultrasound guidance may be used to guide aspiration via a route that avoids overlying cellulitis.</p><p>A septic joint must be distinguished from postinjection flare (see <a class="local">'Postinjection flare'</a> below). Clinical features favoring infection include symptoms starting after 48 hours from injection, symptoms lasting longer than 48 hours, a crescendo pattern of pain, redness or drainage around the injection site, and fever or malaise. (See  <a class="medical medical_review" href="/d/html/7666.html" rel="external">"Septic arthritis in adults"</a>.)</p><p>There is inconclusive evidence that intraarticular glucocorticoid injection preceding total joint arthroplasty of a large joint will increase the probability of septic joint as a complication of the surgery. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7985.html" rel="external">"Intraarticular and soft tissue injections: What agent(s) to inject and how frequently?", section on 'Contraindications'</a>.)</p><p>A detailed discussion on the diagnosis and management of septic arthritis can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/7666.html" rel="external">"Septic arthritis in adults"</a>.)</p><p class="headingAnchor" id="H1735738384"><span class="h2">Septic bursitis</span><span class="headingEndMark"> — </span>The superficial or subcutaneous bursae are predisposed to infection as a result of skin trauma. Septic bursitis can result from direct inoculation due to puncture of the overlying skin during an injection. (See  <a class="medical medical_review" href="/d/html/7650.html" rel="external">"Septic bursitis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">NONINFECTIOUS COMPLICATIONS</span></p><p class="headingAnchor" id="H76108068"><span class="h2">Technique-related</span></p><p class="headingAnchor" id="H1710529578"><span class="h3">Bleeding</span><span class="headingEndMark"> — </span>Local bleeding is uncommon in patients without a bleeding diathesis or who are not on anticoagulation. Holding pressure over the puncture site with sterile gauze is typically sufficient to stop local venous bleeding. A rare complication of hemarthrosis due to an arterioarticular fistula after arthrocentesis has been described [<a href="#rid6">6</a>]. The risk of bleeding complications in patients receiving therapeutic anticoagulation is low and is discussed in detail separately (see  <a class="medical medical_review" href="/d/html/7986.html" rel="external">"Joint aspiration or injection in adults: Technique and indications", section on 'Approach to the patient on anticoagulants'</a>). Using ultrasound guidance for procedures may decrease the likelihood of bleeding complications, but the rarity of this complication makes it difficult to study [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H68390397"><span class="h3">Tendon rupture</span><span class="headingEndMark"> — </span>Tendon rupture appears to be associated with injections placed directly within tendons and may be accelerated by underlying tendon pathology. Tendon rupture is most commonly encountered when undiluted glucocorticoid is injected near the rotator cuff or near the insertion of the long head of the biceps tendon. This complication may be more common with the posterior approach (which can be directed upward in the direction of the subdeltoid bursae and rotator cuff) than with the anterior approach (which is only intraarticular). (See  <a class="medical medical_review" href="/d/html/239.html" rel="external">"Rotator cuff tendinopathy", section on 'Glucocorticoids'</a>.)</p><p class="headingAnchor" id="H1823075699"><span class="h3">Neurovascular damage</span><span class="headingEndMark"> — </span>Nerve atrophy or necrosis occurs when glucocorticoids enter the nerve sheath directly, an event that usually occurs only with carpal tunnel injections that come quite close to the median nerve. This complication can generally be avoided if the procedure is done by a subspecialist with specific training and knowledge of regional anatomy (eg, a hand surgeon or a rheumatologist). Ultrasound guidance may also be helpful if available. (See  <a class="medical medical_review" href="/d/html/5287.html" rel="external">"Carpal tunnel syndrome: Treatment and prognosis", section on 'Glucocorticoid injection'</a>.)</p><p class="headingAnchor" id="H4202871576"><span class="h2">Glucocorticoid-associated toxicity</span></p><p class="headingAnchor" id="H3996277489"><span class="h3">Postinjection flare</span><span class="headingEndMark"> — </span>Postinjection flare is one of the more common acute side effects of an intraarticular glucocorticoid injection, occurring after approximately 5 percent of injections [<a href="#rid8">8</a>]. It is characterized by a localized inflammatory response that typically occurs and resolves within 48 hours after injection. Postinjection flares are thought to result from a chemical synovitis in response to the crystals in the glucocorticoid solution. <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">Triamcinolone</a>, which is less soluble than the other more commonly used preparations, is associated with more postinjection flares [<a href="#rid9">9,10</a>].</p><p>In some cases, the flare can be difficult to distinguish from iatrogenic septic arthritis. One helpful clue is that most iatrogenic joint infections seem to develop clinical signs a bit more slowly than a postinjection flare. In addition, postinjection flares primarily occur with soft tissue, tendon, or trigger point injections, while infections are rare and occur primarily with intraarticular injections.</p><p class="headingAnchor" id="H286701049"><span class="h3">Facial flushing</span><span class="headingEndMark"> — </span>Facial flushing after glucocorticoid injection has been reported in as many as 10 percent of patients and is more common in women [<a href="#rid8">8</a>]. The onset of flushing is usually within a few hours after injection and may persist for a few days [<a href="#rid11">11</a>]. Facial flushing may often be described as an "allergic reaction" by some patients but is probably not a true allergy in most patients.</p><p class="headingAnchor" id="H3786215013"><span class="h3">Local skin or fat changes</span><span class="headingEndMark"> — </span>Skin or fat atrophy and skin hypopigmentation are more commonly observed with injections of superficial structures (eg, ganglia, tendon sheath) but can also occur with deeper injections. Skin or fat atrophy are observed clinically as a depressed area of skin, which may develop weeks or months after the injection. Darkly pigmented skin is more susceptible to hypopigmentation and depigmentation, and patients should be informed of such a potential complication (<a class="graphic graphic_picture graphicRef74337" href="/d/graphic/74337.html" rel="external">picture 1</a>).</p><p class="headingAnchor" id="H1332181043"><span class="h3">Osteonecrosis</span><span class="headingEndMark"> — </span>An uncommon complication of intraarticular glucocorticoids is osteonecrosis (ischemic or avascular necrosis of bone) [<a href="#rid12">12-14</a>]. The risk of this complication is reported to range from less than 0.1 to 3 percent of injected joints [<a href="#rid15">15,16</a>]. However, the former figure seems more consistent with clinical practice. It has been hypothesized that the severity of the underlying joint disease may contribute more to this risk than the injection itself.</p><p class="headingAnchor" id="H1166980703"><span class="h3">Cartilage damage</span><span class="headingEndMark"> — </span>There is limited evidence suggesting that repeated intraarticular glucocorticoid injections may result in cartilage loss for patients with osteoarthritis [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial with 140 patients with symptomatic knee osteoarthritis, those who received intraarticular <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> every three months for two years demonstrated greater cartilage volume loss on magnetic resonance imaging (MRI) compared with those who received placebo injections [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another randomized trial with two-year follow-up found no difference in adverse effects when comparing intraarticular glucocorticoids with placebo injections; however, radiography was used to assess progression of osteoarthritis, which is a less sensitive measure of cartilage damage compared with MRI [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A cohort study of 656 patients receiving an average of two injections over five years confirmed that infrequent injection does not raise the rate of total knee replacement or radiographic progression as determined by radiography [<a href="#rid19">19</a>].</p><p></p><p>In addition, rare cases of rapidly destructive hip disease have been described in association with intraarticular glucocorticoid injections in the hip. A case-control study of patients undergoing hip arthroplasty noted that the rate of developing rapidly destructive hip disease was higher among patients who received intraarticular glucocorticoid injections, and the risk was positively correlated with higher doses of glucocorticoids and a higher number of injections [<a href="#rid20">20</a>]. The role for intraarticular glucocorticoid injections in hip osteoarthritis is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/119317.html" rel="external">"Management of hip osteoarthritis", section on 'Limited role of intraarticular glucocorticoids'</a>.)</p><p>It is possible that the risk of joint cartilage damage is comparatively less when glucocorticoid injections are used to control flares of inflammatory arthritis (eg, rheumatoid arthritis), since not treating the underlying disease may also cause cartilage damage. In one small retrospective study, repeated glucocorticoid injection into large joints affected by rheumatoid arthritis did not result in an increased rate of total joint arthroplasty in those joints during long-term follow-up [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H3"><span class="h3">Systemic effects</span><span class="headingEndMark"> — </span>Intraarticular glucocorticoids do have some degree of systemic absorption and can therefore cause systemic adverse effects. A more common adverse effect is transient hyperglycemia, which may be problematic for patients with diabetes mellitus (DM). However, patients generally experience higher blood glucose values for one to two days, which rarely poses a significant clinical risk when the DM is well controlled. (See  <a class="medical medical_review" href="/d/html/109527.html" rel="external">"Comorbidities that impact management of osteoarthritis", section on 'Diabetes mellitus'</a>.)</p><p>A rare side effect related to systemic absorption of intraarticular glucocorticoids is suppression of the hypothalamic-pituitary axis [<a href="#rid22">22</a>]. Other rare systemic complications that can be seen are ecchymoses, menstrual irregularity, accelerated cataract formation, and osteoporosis. Bone metabolism markers suggest that bone metabolism recovers completely in one to two weeks after the injection [<a href="#rid18">18,23</a>]. Glucocorticoid-induced osteoporosis is probably not a major concern for the majority of patients who have reasonably long intervals between their injections. (See  <a class="medical medical_review" href="/d/html/2032.html" rel="external">"Clinical features and evaluation of glucocorticoid-induced osteoporosis"</a> and  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H545107760"><span class="h3">Allergic reaction</span><span class="headingEndMark"> — </span>The incidence of allergic reactions is unknown. Facial flushing may often be misinterpreted as an allergic reaction by some patients. (See <a class="local">'Facial flushing'</a> above.)</p><p class="headingAnchor" id="H4102506635"><span class="h3">Other</span><span class="headingEndMark"> — </span>Other rare complications that have been described include dystrophic calcification, Charcot-like arthropathy, or embolia cutis medicamentosa (also known as livedoid dermatitis and Nicolau syndrome).</p><p class="headingAnchor" id="H2951889"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infectious complications</strong> – Bacteria can be introduced into the joint space or nearby bursae during joint aspiration or injection. Iatrogenic septic arthritis from a joint procedure is a rare but serious complication that occurs in 1 out of every 1000 to 3000 procedures. Infection, rather than the more common postinjection flare, should be suspected if the flare lasts longer than or begins later than 48 hours after injection. Septic bursitis can result from direct inoculation due to puncture of the overlying skin during an injection. (See <a class="local">'Septic arthritis'</a> above and  <a class="medical medical_review" href="/d/html/7666.html" rel="external">"Septic arthritis in adults"</a> and  <a class="medical medical_review" href="/d/html/7650.html" rel="external">"Septic bursitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique-related complications</strong> – Noninfectious complications that are directly related to technique include bleeding, tendon rupture, and neurovascular damage. Tendon rupture appears to be associated with injections placed directly within tendons and may be accelerated by underlying tendon pathology. Nerve atrophy or necrosis occurs when glucocorticoids enter the nerve sheath directly, as can happen with carpal tunnel injections. (See <a class="local">'Tendon rupture'</a> above and <a class="local">'Neurovascular damage'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid-associated adverse effects</strong> – Complications of intraarticular glucocorticoid injections related to the medication include postinjection flare, facial flushing, local skin or fat changes, osteonecrosis, cartilage damage, systemic effects (eg, hyperglycemia), allergic reactions, and other rare complications (eg dystrophic calcification, Charcot-like arthropathy, or embolia cutis medicamentosa [also known as livedoid dermatitis and Nicolau syndrome]). (See <a class="local">'Glucocorticoid-associated toxicity'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Geirsson AJ, Statkevicius S, Víkingsson A. Septic arthritis in Iceland 1990-2002: increasing incidence due to iatrogenic infections. Ann Rheum Dis 2008; 67:638.</a></li><li><a class="nounderline abstract_t">Petersen SK, Hansen I, Andreasen RA. Low frequency of septic arthritis after arthrocentesis and intra-articular glucocorticoid injection. Scand J Rheumatol 2019; 48:393.</a></li><li><a class="nounderline abstract_t">Ross K, Mehr J, Carothers B, et al. Outbreak of Septic Arthritis Associated with Intra-Articular Injections at an Outpatient Practice - New Jersey, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:777.</a></li><li><a class="nounderline abstract_t">Xu C, Peng H, Chai W, et al. Inadvertent Introduction of Tissue Coring Into Joints During Arthrocentesis: An Experimental Study. Med Sci Monit 2017; 23:3571.</a></li><li><a class="nounderline abstract_t">Smyth TT, Chirino-Trejo M, Carmalt JL. In vitro assessment of bacterial translocation during needle insertion through inoculated culture media as a model of arthrocentesis through cellulitic tissue. Am J Vet Res 2015; 76:877.</a></li><li><a class="nounderline abstract_t">Morag Y, Ford MK, Jacobson JA, Jamadar DA. Sonographic diagnosis of an arterioarticular fistula following knee arthrocentesis. J Clin Ultrasound 2006; 34:207.</a></li><li><a class="nounderline abstract_t">Shah A, Barnes RM, Rocco LE, et al. Measuring success: A comparison of ultrasound and landmark guidance for knee arthrocentesis in a cadaver model. Am J Emerg Med 2023; 71:157.</a></li><li class="breakAll">Naredo E, Rull M. Aspiration and injection of joints and periarticular tissue and intralesional therapy. In: Rheumatology, Sixth, Hochberg MC, Silman AJ, Smolen JS, et al (Eds), Elsevier Mosby, 2015. Vol 1, p.544.</li><li><a class="nounderline abstract_t">Young P, Homlar KC. Extreme Postinjection Flare in Response to Intra-Articular Triamcinolone Acetonide (Kenalog). Am J Orthop (Belle Mead NJ) 2016; 45:E108.</a></li><li><a class="nounderline abstract_t">MacMahon PJ, Eustace SJ, Kavanagh EC. Injectable corticosteroid and local anesthetic preparations: a review for radiologists. Radiology 2009; 252:647.</a></li><li><a class="nounderline abstract_t">Cole BJ, Schumacher HR Jr. Injectable corticosteroids in modern practice. J Am Acad Orthop Surg 2005; 13:37.</a></li><li><a class="nounderline abstract_t">Thompson AR, Ensrud ER. Rapid Onset of Femoral Head Osteonecrosis After a Single Intra-articular Hip Joint Injection of Corticosteroid. Am J Phys Med Rehabil 2020; 99:e54.</a></li><li><a class="nounderline abstract_t">Kontovazenitis PI, Starantzis KA, Soucacos PN. Major complication following minor outpatient procedure: osteonecrosis of the knee after intraarticular injection of cortisone for treatment of knee arthritis. J Surg Orthop Adv 2009; 18:42.</a></li><li><a class="nounderline abstract_t">Kompel AJ, Roemer FW, Murakami AM, et al. Intra-articular Corticosteroid Injections in the Hip and Knee: Perhaps Not as Safe as We Thought? Radiology 2019; 293:656.</a></li><li><a class="nounderline abstract_t">Sparling M, Malleson P, Wood B, Petty R. Radiographic followup of joints injected with triamcinolone hexacetonide for the management of childhood arthritis. Arthritis Rheum 1990; 33:821.</a></li><li><a class="nounderline abstract_t">Neidel J, Boehnke M, Küster RM. The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis. Arthritis Rheum 2002; 46:1620.</a></li><li><a class="nounderline abstract_t">McAlindon TE, LaValley MP, Harvey WF, et al. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial. JAMA 2017; 317:1967.</a></li><li><a class="nounderline abstract_t">Raynauld JP, Buckland-Wright C, Ward R, et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003; 48:370.</a></li><li><a class="nounderline abstract_t">Latourte A, Rat AC, Omorou A, et al. Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5 Years? Arthritis Rheumatol 2022; 74:1343.</a></li><li><a class="nounderline abstract_t">Okike K, King RK, Merchant JC, et al. Rapidly Destructive Hip Disease Following Intra-Articular Corticosteroid Injection of the Hip. J Bone Joint Surg Am 2021; 103:2070.</a></li><li><a class="nounderline abstract_t">Roberts WN, Babcock EA, Breitbach SA, et al. Corticosteroid injection in rheumatoid arthritis does not increase rate of total joint arthroplasty. J Rheumatol 1996; 23:1001.</a></li><li><a class="nounderline abstract_t">Mader R, Lavi I, Luboshitzky R. Evaluation of the pituitary-adrenal axis function following single intraarticular injection of methylprednisolone. Arthritis Rheum 2005; 52:924.</a></li><li><a class="nounderline abstract_t">Emkey RD, Lindsay R, Lyssy J, et al. The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:277.</a></li></ol></div><div id="topicVersionRevision">Topic 7977 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901088" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Septic arthritis in Iceland 1990-2002: increasing incidence due to iatrogenic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31146626" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Low frequency of septic arthritis after arthrocentesis and intra-articular glucocorticoid injection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28749922" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Outbreak of Septic Arthritis Associated with Intra-Articular Injections at an Outpatient Practice - New Jersey, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28733573" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Inadvertent Introduction of Tissue Coring Into Joints During Arthrocentesis: An Experimental Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26413825" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : In vitro assessment of bacterial translocation during needle insertion through inoculated culture media as a model of arthrocentesis through cellulitic tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16615056" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Sonographic diagnosis of an arterioarticular fistula following knee arthrocentesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37406477" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Measuring success: A comparison of ultrasound and landmark guidance for knee arthrocentesis in a cadaver model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37406477" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Measuring success: A comparison of ultrasound and landmark guidance for knee arthrocentesis in a cadaver model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26991574" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Extreme Postinjection Flare in Response to Intra-Articular Triamcinolone Acetonide (Kenalog).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717750" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Injectable corticosteroid and local anesthetic preparations: a review for radiologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15712981" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Injectable corticosteroids in modern practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32195718" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Rapid Onset of Femoral Head Osteonecrosis After a Single Intra-articular Hip Joint Injection of Corticosteroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19327266" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Major complication following minor outpatient procedure: osteonecrosis of the knee after intraarticular injection of cortisone for treatment of knee arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31617798" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Intra-articular Corticosteroid Injections in the Hip and Knee: Perhaps Not as Safe as We Thought?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2363737" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Radiographic followup of joints injected with triamcinolone hexacetonide for the management of childhood arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115194" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The efficacy and safety of intraarticular corticosteroid therapy for coxitis in juvenile rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28510679" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients With Knee Osteoarthritis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12571845" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35289131" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5 Years?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34550909" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Rapidly Destructive Hip Disease Following Intra-Articular Corticosteroid Injection of the Hip.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8782130" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Corticosteroid injection in rheumatoid arthritis does not increase rate of total joint arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15751089" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of the pituitary-adrenal axis function following single intraarticular injection of methylprednisolone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8849379" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
